The Zygote: Totipotency, Embryonic Genome Activation and Parental Genome Contributions

A comprehensive guide to zygote biology for clinical embryology students — covering totipotency, the maternal-to-embryonic transition, embryonic genome activation, and the distinct contributions of each parental genome.

What This Article Covers

The zygote — the single cell produced by fertilisation — is totipotent, runs entirely on maternal molecular machinery for its first few days, and contains two genomes of unequal epigenetic status that must be reprogrammed before they can cooperate. This article examines totipotency and the cellular potency hierarchy, the maternal-to-embryonic transition and embryonic genome activation, and the distinct contributions of each parental genome including genomic imprinting and its clinical consequences.

Part I: Totipotency

What Is the Zygote?

The zygote is the single diploid cell (46 chromosomes) produced by the fusion of a haploid spermatozoon and a haploid secondary oocyte at fertilisation. It is the first cell of the new organism — genetically unique, and the only truly totipotent cell in human development. In IVF, the zygote is identified at the Day 1 fertilisation check (16–18 hours post-insemination) by the presence of two pronuclei (2PN) and two polar bodies.

The Cellular Potency Hierarchy

Developmental potential is organised into a strict hierarchy. Totipotent cells can give rise to all cells of the organism — both embryonic and extra-embryonic tissues including the placenta, yolk sac, and amnion. Only the zygote and the very earliest blastomeres up to approximately the 4-cell stage are truly totipotent. Pluripotent cells can give rise to all three primary germ layers (ectoderm, mesoderm, endoderm) but not extra-embryonic tissues — this describes the Inner Cell Mass (ICM) of the blastocyst and embryonic stem cells (ESCs). Multipotent cells produce several types within a tissue lineage, oligopotent cells produce only a few types, and unipotent cells produce only one cell type while retaining self-renewal capacity.

What Makes the Zygote Totipotent?

Totipotency is a property of both the genome and the cellular context — the specific molecular environment of the oocyte cytoplasm that reprogrammes chromatin into a totipotent state. After fertilisation, both the sperm and oocyte genomes undergo extensive epigenetic reprogramming. The paternal genome undergoes rapid, active DNA demethylation within hours via TET3 enzymes. The maternal genome undergoes slower, passive demethylation over subsequent cleavage divisions. Both genomes converge on a hypomethylated, open-chromatin state by the morula/blastocyst stage — the molecular foundation of totipotency.

The zygote and very early blastomeres express a specific set of totipotency factors not found in pluripotent cells. DUX4 is the master transcription factor of the totipotent state, expressed specifically at the 2–4 cell stage. It activates ZSCAN4, which promotes telomere elongation in cleavage-stage embryos, and HERV-H elements — endogenous retroviral sequences that act as enhancers and promoters for totipotency-associated genes. The transition from totipotency to pluripotency occurs at the blastocyst stage, when ICM cells activate the OCT4/NANOG/SOX2 network and cease expressing DUX4.

Part II: Embryonic Genome Activation

The Maternal Programme

For the first few days of development, the embryo does not use its own DNA. It runs entirely on a stockpile of maternal mRNA and proteins synthesised and stored in the oocyte during oogenesis. This maternal programme includes thousands of maternal mRNA species encoding proteins for cell division (Cyclin B), meiotic arrest (c-Mos), DNA repair, and pluripotency factors. All ribosomes, mitochondria, and regulatory non-coding RNAs during this period are also of maternal origin.

The Maternal-to-Embryonic Transition

The Maternal-to-Embryonic Transition (MET) is the coordinated process by which the maternal molecular programme is progressively dismantled, the embryonic genome is gradually activated, and developmental control passes from maternal to embryonic regulation. In humans, this spans approximately Days 2–4 of development, from the 2-cell to the 8-cell stage. Its failure is the primary cause of embryo developmental arrest in IVF cultures.

EGA timing is species-specific and clinically important. In humans, a minor EGA wave occurs at the 2-cell stage followed by the major EGA wave at the 4–8 cell stage. In the mouse, EGA occurs at the 2-cell stage — meaning findings from mouse models cannot be directly extrapolated to human embryo development. In bovine embryos, EGA occurs at the 8–16 cell stage.

Mechanisms of EGA

EGA involves chromatin remodelling through histone variant exchange and acetylation, converting heterochromatin to transcriptionally accessible euchromatin. DUX4 acts as the primary pioneer transcription factor, opening chromatin at EGA in humans. Simultaneously, maternal mRNAs are cleared through the CCR4-NOT deadenylase complex, which shortens poly-A tails and marks transcripts for degradation, assisted by embryo-derived microRNAs. RNA Polymerase II pre-initiation complexes are then assembled at gene promoters and HERV-H retroviral elements are reactivated, acting as alternative promoters and enhancers for nearby developmental genes.

Developmental arrest at the 4–8 cell stage is the most common cause of embryo loss after fertilisation, accounting for 20–40% of all 2PN embryos in an IVF cycle. The causes include poor oocyte cytoplasmic maturity, sperm DNA fragmentation, chromosomal aneuploidy, suboptimal culture conditions, and mitochondrial dysfunction. Extended culture to blastocyst on Day 5–6 has become standard precisely because it allows embryos to self-select by successfully completing EGA.

Part III: Parental Genome Contributions

The Maternal Contribution

The oocyte provides the entire cytoplasm of the zygote — all organelles, ribosomes, translation machinery, cytoskeletal components, and regulatory RNAs. All mitochondria in the zygote are maternally derived, meaning mitochondrial DNA is exclusively maternally inherited. This has direct clinical implications for mitochondrial genetic diseases, as affected mothers pass mtDNA mutations to all their children. The maternal mRNA stockpile drives all development before EGA, making oocyte cytoplasmic quality the primary determinant of embryo developmental competence up to Day 2–3. The oocyte also carries specific maternal genomic imprints established during oogenesis, which must be precisely maintained through all subsequent cell divisions.

Notably, human oocytes do not contain functional centrioles — they are eliminated during oogenesis. This makes the sperm's proximal centriole an essential, non-negotiable paternal contribution.

The Paternal Contribution

The sperm contributes 23 chromosomes, the proximal centriole, and PLCzeta to the zygote. The proximal centriole is the most important non-chromosomal paternal contribution — it recruits maternal centrosomal proteins and reassembles as the sperm aster that organises the first cleavage spindle. Without it, the chromosomes of the zygote cannot be correctly segregated. PLCzeta triggers the calcium oscillations that activate the oocyte. The paternal genome also carries epigenetic imprinting marks established during spermatogenesis at specific imprinting control regions (ICRs). Emerging research additionally shows that sperm carry small non-coding RNAs that may influence early embryonic gene expression — a form of epigenetic transmission beyond DNA sequence.

Genomic Imprinting

Genomic imprinting is the epigenetic mechanism by which specific genes are expressed in a parent-of-origin-specific manner — one parental allele is expressed while the other is silenced. Approximately 100–150 genes in the human genome are imprinted. A normal embryo cannot develop with only a maternal or only a paternal genome — both contributions are absolutely required. This was demonstrated in the 1980s when gynogenetic embryos (two maternal genomes) and androgenetic embryos (two paternal genomes) both failed to develop normally.

During gametogenesis, all previous imprints are erased and new sex-specific imprints are established — paternal imprints during spermatogenesis, maternal imprints during oogenesis. These imprints are then maintained throughout all subsequent somatic cell divisions by DNMT1 and specialised factors including ZFP57 and TRIM28, even as the genome is globally demethylated during reprogramming.

The leading evolutionary explanation for imprinting is the parental conflict hypothesis — paternally expressed imprinted genes such as IGF2 and DLK1 promote fetal growth and placental function, while maternally expressed imprinted genes such as H19 and CDKN1C suppress growth and conserve maternal resources.

Imprinting Disorders

When imprinting is disrupted — by deletion, uniparental disomy (UPD), or methylation errors — specific clinical syndromes result. Beckwith-Wiedemann Syndrome arises from a chromosome 11p15 imprinting defect, causing overgrowth, macroglossia, omphalocele, and an increased risk of Wilms tumour. It is overrepresented in IVF-conceived children, particularly after ICSI and frozen-thawed embryo transfer, likely due to culture conditions affecting ICR methylation maintenance. Silver-Russell Syndrome involves hypomethylation of the H19/IGF2 ICR1, resulting in reduced IGF2 expression and intrauterine growth restriction.

Prader-Willi Syndrome and Angelman Syndrome affect the same chromosomal region — 15q11-13 — yet produce completely different syndromes depending on which parental copy is absent. Loss of the paternal 15q11-13 contribution causes Prader-Willi Syndrome (neonatal hypotonia, childhood hyperphagia and obesity, intellectual disability), while loss of the maternal 15q11-13 contribution causes Angelman Syndrome (severe intellectual disability, absent speech, seizures, happy affect). This contrast is one of the most powerful demonstrations of genomic imprinting in human medicine.

UPD is a condition where both copies of a chromosome come from one parent. It cannot be detected by standard karyotype and requires SNP array or microsatellite analysis. Standard PGT-A also cannot detect UPD — a UPD embryo may appear euploid on copy number analysis while carrying an imprinting disorder.

Conclusion

The zygote's totipotency, its reliance on maternal molecular machinery before EGA, and the non-equivalent contributions of its two parental genomes together explain why development requires perfect coordination between gamete quality, chromatin reprogramming, and imprinting maintenance. For clinical embryologists, these mechanisms directly explain embryo arrest patterns, imprinting disorder risks in ART, and the rationale for blastocyst culture.

Disclaimer

This article is for educational purposes only, prepared by the SEART Editorial Team for clinical embryology students. It does not constitute medical advice or clinical guidance. Protocols and reference values may vary between institutions and evolve with emerging evidence. Readers should consult current literature and qualified supervisors for practice-specific guidance. Content reviewed by SEART clinical embryology faculty.